Michel Vounatsos is a biopharmaceutical executive and former Chief Executive Officer of Biogen Inc., where he served as CEO and board member from 2017 to 2022 after joining the company as Executive Vice President and Chief Commercial Officer in 2016.( During his tenure at Biogen, he led the company’s global neuroscience-focused portfolio and oversaw major strategic and commercial initiatives, later remaining in the role while the board searched for his successor.( He has been identified in securities filings as a corporate insider of Biogen Inc. through his executive and board positions.

Vounatsos brings over 25 years of global pharmaceutical leadership, having spent two decades at Merck & Co. (MSD) in roles of increasing responsibility across Europe, China, and the United States, including President of MSD China and President of Primary Care and Merck Customer Centricity.( He currently serves on the board of Zai Lab, where he chairs the Commercial Committee, and has held other public company board roles such as at Revvity, Inc., in addition to advisory and supervisory board positions at Tsinghua University’s School of Pharmaceutical Sciences and the Liryc Institute at the University of Bordeaux.( Vounatsos holds medical training with a C.S.C.T. (Certificate of Clinical and Therapeutic Synthesis) in Medicine from Université Victor Segalen Bordeaux II and an MBA from HEC Paris, underpinning his career at the intersection of clinical science and biopharmaceutical business leadership.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.